Status:
COMPLETED
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Huntington Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. The disease progression is classically characterized by a c...
Detailed Description
We proposed a randomized controlled trial, including 180 patients, in 3 groups: Olanzapine, Tetrabenazine and Tiapride, followed during 12 months. These treatments have been selected according their p...
Eligibility Criteria
Inclusion
- Symptomatic disease with motor, behavioural and/or psychiatric disorder required medical treatment.
- HD diagnosed with abnormal number of CAG repeats: 38 ≤ nucleotide expansion (CAG) (amendment n°5 suppressed the limit ≤ 48)
- Neuroleptic Prescription required.
- Age ≥ 18 (amendment n°5 suppressed the limit ≤ 65 years old)
- Patient gave its written consent
- Realization of medical examination and a Electroencephalogram
Exclusion
- Severe cognitive impairment or neuropsychiatric troubles.
- Existing diabetes.
- Neuroleptic prescription forbidden according to the neurologist decision.
- Current participation to another clinical trial.
- No drug compliance to previous treatment.
- No national health insurance affiliation
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 28 2017
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00632645
Start Date
April 1 2009
End Date
April 28 2017
Last Update
January 19 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Henri Mondor
Créteil, France, 94